Immunovaccine to Highlight Clinical Data for Its Lead Candidate in Oral Presentation at 54th Annual Meeting of the American S...
April 26 2018 - 7:05AM
Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage
immuno-oncology company, today announced that its abstract has been
selected for an oral presentation at the upcoming 2018 American
Society of Clinical Oncology (ASCO) Annual Meeting, which takes
place June 1-5 in Chicago, IL. The presentation will include an
update on the DeCidE1 (Dpx-Survivac with CyclophosphamIDe and
Epacadostat) clinical trial, which Immunovaccine is conducting in
collaboration with Incyte Corporation. The Phase 1b/2 study is
evaluating the combination of its lead candidate, DPX-Survivac,
Incyte’s IDO-1 inhibitor epacadostat, and low dose cyclophosphamide
in patients with advanced, recurrent ovarian cancer. Immunovaccine
announced initial results from this trial in December 2017.
“Despite advances in other cancer treatment regimens, ovarian
cancer remains a particularly difficult-to-treat disease, and one
that represents one of the most underserved areas of the treatment
landscape,” said Frederic Ors, Chief Executive Officer at
Immunovaccine. “We look forward to providing this update on our
innovative clinical program alongside our industry peers and
partners at this important medical meeting.”
Oral presentation details are as follows:
Session Title: Engaging the Immune System in
Ovarian CancerLocation: S406Abstract
Number: 5510Title: “Clinical data from
the DeCidE1 trial: Assessing the first combination of DPX-Survivac,
low dose cyclophosphamide (CPA), and epacadostat (INCB024360) in
subjects with stage IIc-IV recurrent epithelial ovarian
cancer.”Presentation Date and Time: Sunday, June
3, 2018, 9:57 AM - 10:09 AM CTPresenter: Oliver
Dorigo, MD, PhD, Associate Professor of Obstetrics and Gynecology
(Oncology), Stanford University Medical Center, Stanford, CA,
DeCideE1 Clinical Investigator and Lead Author
Following the presentation at ASCO, Immunovaccine will post the
presentation on the ‘Events and Presentations’ page on its website:
www.imvaccine.com.
About DPX-Survivac DPX-Survivac consists of
survivin-based peptide antigens formulated in Immunovaccine’s
proprietary immune-activating delivery technology. DPX-Survivac is
thought to work by eliciting a cytotoxic T cell immune response
against cells presenting survivin peptides. Survivin, recognized by
the National Cancer Institute (NCI) as a promising
tumor-associated antigen, is broadly over-expressed in most cancer
types, and plays an essential role in antagonizing cell death,
supporting tumor-associated angiogenesis, and promoting resistance
to anti-cancer therapies. Immunovaccine has identified over 15
cancer indications in which the over-expression of survivin can be
targeted by DPX-Survivac. DPX-Survivac received Fast Track
designation from the U.S. Food and Drug
Administration (FDA) as maintenance therapy in advanced
ovarian cancer, as well as orphan drug designation status from
the U.S. FDA and the European Medicines
Agency (EMA) in the ovarian cancer indication.
About Immunovaccine Immunovaccine
Inc. is a clinical stage biopharmaceutical company dedicated
to making immunotherapy more effective, more broadly applicable,
and more widely available to people facing cancer and other serious
diseases. Immunovaccine is pioneering a new class of
immunotherapies based on the Company’s proprietary drug delivery
platform. This patented technology leverages a novel mechanism of
action that enables the reprogramming of immune cells in vivo,
which are aimed at generating powerful new synthetic therapeutic
capabilities. Immunovaccine’s lead candidate, DPX-Survivac, is a T
cell activating immunotherapy that combines the utility of the
platform with a target: survivin. Immunovaccine is currently
conducting three Phase 2 studies with Incyte and Merck assessing
DPX-Survivac as a combination therapy in ovarian cancer and diffuse
large B-cell lymphoma. Connect at www.imvaccine.com.
Immunovaccine Forward-Looking Statements This
press release contains forward-looking information under applicable
securities law. All information that addresses activities or
developments that we expect to occur in the future is
forward-looking information. Forward-looking statements are based
on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a
representation that any of them will be achieved. Actual results
may differ materially from those set forth in this press release
due to risks affecting the Company, including access to capital,
the completion of clinical trials and receipt of all regulatory
approvals. Immunovaccine Inc. assumes no responsibility
to update forward-looking statements in this press release except
as required by law.
Contacts for Immunovaccine:
MEDIA Mike Beyer, Sam Brown Inc. T:
(312) 961-2502 E: mikebeyer@sambrown.com
INVESTOR RELATIONS Pierre Labbé, Chief
Financial Officer T: (902) 492-1819 E: info@imvaccine.com
Patti Bank, Managing Director, Westwicke
Partners O: (415) 513-1284 T: (415) 515-4572
E: patti.bank@westwicke.com
IMV (TSX:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMV (TSX:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024